Search Results - technology+classifications+%3e+therapeutic+modalities+%3e+antibodies

28 Results

Sort By:

A Novel and Unique Set of Human Antibodies to Human Resistin and to Human Resitin-like Molecule Beta (RELMB) that can be used to Target these Proteins in Human Disease

Unmet NeedAutoinflammatory responses, your body’s innate defense mechanism against infections and stressors, can become overactive and cause chronic inflammation in various tissues and organs. Inflammatory diseases affect more than 200 million people worldwide and include pulmonary hypertension, scleroderma, rheumatoid arthritis, pulmonary fibrosis,...

Published: 3/13/2025 | Inventor(s): Roger Johns

Keywords(s): Antibodies, Biologics, Cardiovascular Diseases, Disease Indication, Hypertension, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Biologics, Clinical and Disease Specializations > Cardiovascular, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Cardiovascular > Hypertension

Compositions and Methods for Treating Diseases and Conditions Associated with Activation of the NLRP3 Inflammasome

Published: 3/14/2025 | Inventor(s): Roger Johns

Keywords(s):

Sustained release formulations for fat reduction

JHU Ref #: C18159Value Proposition· Sustained release of small molecule that depletes white fat· Local injectable administration with less intense dosing regimenUnmet Need· Excessive white fat accumulation, commonly associated with obesity, is a significant health concern that impacts metabolic, cardiovascular, and endocrine systems....

Published: 3/14/2025 | Inventor(s): Laura Ensign-Hodges, Yub Raj Neupane, Fatemeh Rajaii

Keywords(s):

Category(s): Clinical and Disease Specializations > Endocrinology > Thyroid Disorders, Clinical and Disease Specializations > Metabolic Diseases > Obesity, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Small Molecules

Multispecific Antibodies that Induce Downregulation of Programmed Death-ligand 1

Unmet Need: It is estimated that in 2018 there were more than 17 million new cases of cancer worldwide (see ACS). Immune checkpoint therapies have become a powerful treatment route for a wide variety of cancer types and have increased the life expectancy for patients whose disease is refractory to all other therapies. Due to variability in patient response...

Published: 3/14/2025 | Inventor(s): Jamie Spangler, Seth Ludwig, Angela Zhu, Rakeeb Kureshi, Helen Dooley

Keywords(s):

Category(s): Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Antibodies

Antibodies associated with HIV control

Value Proposition· Target associated with viral load reduction identified from a large pool of study participants who had low level viremia· Potential to reduce disease severity in at-risk populations· Proactive approach to lower viral load in individuals who could become infected Unmet NeedHuman immunodeficiency virus (HIV) impacts millions...

Published: 3/14/2025 | Inventor(s): Susan Eshleman, Harry Larman, Kai Kammers, Oliver Laeyendecker, Wendy Grant-McAuley

Keywords(s):

Category(s): Clinical and Disease Specializations > Infectious Diseases > HIV, Clinical and Disease Specializations > Infectious Diseases > HIV/AIDS, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Therapeutic Antibodies

Recombinant anti-PAD4 antibodies as a treatment for lung fibrosis

Value PropositionSelective monoclonal antibody therapy to treat lung fibrosis.Directly targets immune cells to promote a pro-inflammatory pathway that reduces fibrosis.High serum levels are associated with less severe lung disease, decreased fibrosis, and improved survival in a subset of rheumatoid arthritis patients.Broadly applicable to other diseases...

Published: 3/14/2025 | Inventor(s): Erika Darrah, Felipe Andrade, Kristen Demoruelle, Elizabeth Redente

Keywords(s):

Category(s): Clinical and Disease Specializations > Fibrosis, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications, Technology Classifications > Therapeutic Modalities

Polymers for Binding-Triggered Antibody Precipitation and Purification

Value PropositionResults in >97% precipitation yield, >88% elution yield of mAbsSimplified molecular design compared to elastin-like polypeptide (ELP)-based materialsDoes not need additional salt to achieve mAb precipitation and recoveryTechnology DescriptionResearchers at Johns Hopkins have developed a peptide-based platform technology using...

Published: 3/14/2025 | Inventor(s): Honggang Cui, Yi Li, David Stern, XuanKuo Xu, Lye Lin Lock, Jason Mills, Sanchayita Ghose, Zheng Jian Li

Keywords(s):

Category(s): Clinical and Disease Specializations > Immunology, Clinical and Disease Specializations > Research Tools, Technology Classifications > Research Tools > Antibodies, Technology Classifications > Research Tools > Research Antibodies, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Therapeutic Antibodies

Antibody for DNA Degradation

Value Proposition· Autoantibody that promotes DNA degradation to diminish inflammation· Enhances endonuclease DNase1L3 activity· Avoids kidney-mediated inflammatory response Unmet Need· Extracellular DNA, also called cell-free DNA, released from dying cells or activated immune cells can be recognized by the immune system...

Published: 3/14/2025 | Inventor(s): Felipe Andrade, Jose de Jesus Eduardo Gomez-Bañuelos

Keywords(s):

Category(s): Clinical and Disease Specializations > Genetic Diseases > Cystic Fibrosis, Clinical and Disease Specializations > Gastroenterology > Inflammatory Bowel Disease, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Therapeutic Antibodies, Clinical and Disease Specializations > Inflammation > Arthritis

Engineered Cytokine-antibody Fusion for Targeted Expansion of Immune Effector Cells

Unmet NeedGlobal revenue from the cytokine therapeutics market was valued at approximately $16.5 billion in 2018, and cytokine immunotherapy is a promising field of anti-cancer treatments for a broad range of cancer types. In particular, interleukin-2 (IL-2) therapy is shown to stimulate anti-cancer immunity. However, IL-2 activates contradictory immune...

Published: 3/14/2025 | Inventor(s): Jamie Spangler, Jakub Tomala, Michael Leff, Seth Ludwig, Elissa Leonard, Marek Kovar, Jirina Kovarova

Keywords(s): Biologics, Cancers, Disease Indication, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Antibodies, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities > Biologics

Predicting infection severity and antibody treatment

Unmet NeedThe spectrum of COVID-19 symptomatic infection ranges from mild to critical. Severe illness can occur in healthy individuals of any age, but it predominantly occurs in adults with advanced age or certain underlying medical comorbidities (e.g. cardiovascular disease, diabetes, hypertension, chronic lung disease, obesity). Some prediction tools...

Published: 3/14/2025 | Inventor(s): Roger Johns, Qing Lin, John Skinner

Keywords(s):

Category(s): Technology Classifications > Therapeutic Modalities > Antibodies

1 2 3